News

Alliance for new antibiotics
Enlarge image

FundingDenmarkNorway

Alliance for new antibiotics

27.02.2013 - Xellia Pharmaceuticals and the Statens Serum Institute have kicked-off a collaboration to find new medicines against antibiotic-resistant bacteria.

The 4 -year collaboration of the Norwegian firm with Trondheim-based SINTEF Materials and Chemistry  and the Danish Institute (Copenhagen) focusses on developing novel antibiotics to combat multi-drug resistant (MDR), Gram-negative bacteria. Supported with US$3m from the Research Council of Norway, it will target Pseudomonas, Klebsiella, Acinetobacter and Enterobacter species.

Severe sepsis and septic shock due to such infections claim up to 135,000 lives each year in Europe and 215,000 in the US. Resistance to existing antibiotics has become a major healthcare issue worldwide. In the EU alone, infections due to serious hospital-based MDR infections have been reported to cost between €28,500 and €70,100 per surviving patient.

Recently, pan-drug resistant (PDR) and even so-called extensively drug resistant (XDR) Gram-negative bacteria have started to appear, taking the treatment situation to a critical point. The lack of novel antibiotics is significantly compromising the survival and recovery of patients suffering from these infections. At present, only two antibiotic subclasses are still available to treat XDR infections, polymyxins and tigecycline. They have been used for 60-70 years without developing a significant resistance. However, these antibiotics are known to exhibit elevated nephrotoxicity (affecting kidney function) and are, therefore, not ideal for systemic treatment of XDR-infections.

Xellia aims at developing new, polymyxin-like drugs with fewer side-effects. The SINTEF and Statens Serum Institut research groups are specialists in fermentation development and drug testing. Xellia already markets four antibiotics targeting Gram-negative bacteria.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/alliance-for-new-antibiotics.html

DiabetesFrance

01.09.2015 Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EVOLVA (CH)1.49 CHF12.03%
  • TIGENIX (B)1.23 EUR9.82%
  • OREXO (S)49.10 SEK8.39%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-11.67%
  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • PROTHENA PLC (IE)52.70 USD-6.54%

TOP

  • KARO BIO (S)41.90 SEK2568.8%
  • BIOTECH PHARMACON (N)16.80 NOK80.6%
  • TRANSGENE (F)4.86 EUR75.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-49.6%
  • THROMBOGENICS (B)2.85 EUR-42.1%

TOP

  • KARO BIO (S)41.90 SEK4661.4%
  • ADOCIA (F)89.30 EUR409.1%
  • GALAPAGOS (B)53.25 EUR325.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-81.7%
  • BIOTEST (D)20.30 EUR-76.5%

No liability assumed, Date: 03.09.2015